Diagnostic role of C-reactive protein, procalcitonin and lipopolysaccharide-binding protein in discriminating bacterial-community acquired pneumonia from 2009 H1N1 influenza A infection

Tuberculosis and Respiratory Diseases

Volumn 70, Issue 6, 2011, Pages 490-497

  Han, Seon Sook ^a   Kim, Se Hyun ^a   Kim, Woo Jin ^a   Lee, Seung Joon ^a   Ryu, Sook Won ^a   Cheon, Myeong Ju ^a  

^a Kangwon National University   (South Korea)

Author keywords

Bacteria; C Reactive protein; Influenza A virus; Lipopolysaccharide binding protein; Procalcitonin

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; LIPOPOLYSACCHARIDE BINDING PROTEIN; PROCALCITONIN;

ARTICLE; BACTERIAL PNEUMONIA; CLINICAL ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; INFLUENZA A (H1N1); OBSERVATIONAL STUDY; PROSPECTIVE STUDY; VIRUS DIAGNOSIS;

EID: 79960757859     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2011.70.6.490     Document Type: Article

References (22)

1. Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care 2010;14:203.
2. Pfäfflin A, Schleicher E. Inflammation markers in point-of-care testing (POCT). Anal Bioanal Chem 2009;393: 1473-80.
3. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004;363:600-7. (Pubitemid 38264177)
4. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004;39:206-17. (Pubitemid 38971491)
5. Gaïni S, Koldkjaer OG, Pedersen C, Pedersen SS. Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study. Crit Care 2006;10:R53.
6. Schultz MJ, Determann RM. PCT and sTREM-1: the markers of infection in critically ill patients? Med Sci Monit 2008;14:RA241-7.
7. Hopstaken RM, Cals JW, Dinant GJ. Accuracy of lipopolysaccharide-binding protein (LBP) and fibrinogen compared to C-reactive protein (CRP) in differentiating pneumonia from acute bronchitis in primary care. Prim Care Respir J 2009;18:227-30.
8. Schuetz P, Christ-Crain M, Müller B. Biomarkers to improve diagnostic and prognostic accuracy in systemic infections. Curr Opin Crit Care 2007;13:578-85. (Pubitemid 47357461)
9. Müller B, Morgenthaler N, Stolz D, Schuetz P, Müller C, Bingisser R, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007;37:145-52. (Pubitemid 46066494)
10. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults, Clin Infect Dis 2007;44 Suppl 2:S27-72.
11. Bafadhel M, Clark TW, Reid C, Medina MJ, Batham S, Barer MR, et al. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest 2011;139:1410-8.
12. Ahn S, Kim WY, Yoon JY, Sohn CH, Seo DW, Kim SH, et al. Procalcitonin in 2009 H1N1 influenza pneumonia: role in differentiating from bacterial pneumonia. Tuberc Respir Dis 2010;68:205-11.
13. Ingram PR, Inglis T, Moxon D, Speers D. Procalcitonin and C-reactive protein in severe 2009 H1N1 influenza infection. Intensive Care Med 2010;36:528-32.
14. Park HP, Lee JS, Jang YS, Kim MS. Usefulness of procalcitonin in the assessing the severity of community-acquired pneumonia patient. Tuberc Respir Dis 2009;67:430-5.
15. Christ-Crain M, Müller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 2007;30:556-73. (Pubitemid 351182082)
16. Herzum I, Renz H. Inflammatory markers in SIRS, sepsis and septic shock. Curr Med Chem 2008;15:581-7. (Pubitemid 351516814)
17. Masiá M, Gutiérrez F, Llorca B, Navarro JC, Mirete C, Padilla S, et al. Serum concentrations of lipopolysaccharide-binding protein as a biochemical marker to differentiate microbial etiology in patients with community-acquired pneumonia. Clin Chem 2004;50: 1661-4. (Pubitemid 39121236)
18. Masiá M, Gutiérrez F, Padilla S, Soldán B, Mirete C, Shum C, et al. Clinical characterisation of pneumonia caused by atypical pathogens combining classic and novel predictors. Clin Microbiol Infect 2007;13:153-61. (Pubitemid 46115655)
19. Katan M, Christ-Crain M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly 2010;140:w13101.
20. Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 2005; 26:2500-4. (Pubitemid 41676723)
21. Darzy KH, Dixit KC, Shalet SM, Morgenthaler NG, Brabant G. Circadian secretion pattern of copeptin, the C-terminal vasopressin precursor fragment. Clin Chem 2010;56:1190-1.
22. Maeder MT, Staub D, Brutsche MH, Arenja N, Socrates T, Reiter M, et al. Copeptin response to clinical maximal exercise tests. Clin Chem 2010;56:674-6.